Ekso Bionics (EKSO)
(Delayed Data from NSDQ)
$1.23 USD
+0.02 (1.65%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.24 +0.01 (0.81%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Balance Sheet
Fiscal Year End for Ekso Bionics Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 9 | 21 | 40 | 13 | 11 |
Receivables | 6 | 5 | 5 | 3 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 5 | 2 | 2 | 2 |
Other Current Assets | 1 | 1 | 0 | 0 | 0 |
Total Current Assets | 20 | 31 | 48 | 18 | 19 |
Net Property & Equipment | 2 | 3 | 1 | 1 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 6 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 29 | 41 | 49 | 21 | 22 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 2 | 0 | 0 | 2 |
Accounts Payable | 2 | 3 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 2 | 2 | 1 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 1 | 1 | 2 | 1 |
Total Current Liabilities | 8 | 9 | 7 | 5 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 1 | 1 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5 | 4 | 2 | 3 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 2 | 6 | 4 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 16 | 15 | 12 | 16 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 252 | 249 | 246 | 204 | 190 |
Retained Earnings | -239 | -224 | -209 | -199 | -183 |
Other Equity | 0 | 1 | 0 | -1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 25 | 37 | 4 | 7 |
Total Liabilities & Shareholder's Equity | 29 | 41 | 49 | 21 | 22 |
Total Common Equity | 13 | 25 | 37 | 4 | 7 |
Shares Outstanding | 14.80 | 13.10 | 12.60 | 8.30 | 5.80 |
Book Value Per Share | 0.85 | 1.94 | 2.95 | 0.53 | 1.17 |
Fiscal Year End for Ekso Bionics Holdings, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 6 | 9 | 9 | 10 | 13 |
Receivables | 7 | 6 | 6 | 6 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 5 | 5 | 5 | 5 | 6 |
Other Current Assets | 1 | 1 | 1 | 1 | 1 |
Total Current Assets | 19 | 21 | 20 | 22 | 25 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 5 | 5 | 5 | 5 | 5 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 27 | 29 | 29 | 31 | 34 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 1 | 1 | 1 | 1 | 3 |
Accounts Payable | 2 | 2 | 2 | 3 | 3 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 2 | 3 | 2 | 2 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 2 | 2 | 2 | 1 |
Total Current Liabilities | 8 | 7 | 8 | 8 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 2 | 2 | 2 | 2 | 2 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 4 | 5 | 5 | 5 | 3 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 15 | 15 | 16 | 16 | 16 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 256 | 256 | 252 | 250 | 250 |
Retained Earnings | -245 | -243 | -239 | -236 | -233 |
Other Equity | 1 | 0 | 0 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 12 | 14 | 13 | 15 | 18 |
Total Liabilities & Shareholder's Equity | 27 | 29 | 29 | 31 | 34 |
Total Common Equity | 12 | 14 | 13 | 15 | 18 |
Shares Outstanding | 18.40 | 18.10 | 14.80 | 14.20 | 13.80 |
Book Value Per Share | 0.66 | 0.78 | 0.85 | 1.07 | 1.29 |